Follistatin 315 Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Follistatin 315 is a specific isoform of follistatin that is membrane-bound and acts primarily in a localized, autocrine/paracrine manner. It inhibits myostatin and activin locally in muscle tissue, making it of interest for targeted muscle growth applications.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated August 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
How Follistatin 315 Works
Binds activin and myostatin locally within muscle tissue due to heparin-binding domain, providing targeted inhibition rather than systemic effects.
Follistatin 315 FAQ
What is FOLLISTATIN 315?
Follistatin 315 is a tissue-bound isoform of follistatin with more localized myostatin-blocking activity compared to the circulating Follistatin 344 variant.
How does FOLLISTATIN 315 work?
Binds activin and myostatin locally within muscle tissue due to heparin-binding domain, providing targeted inhibition rather than systemic effects.
Is FOLLISTATIN 315 legal to buy?
FOLLISTATIN 315 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy FOLLISTATIN 315?
FOLLISTATIN 315 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does FOLLISTATIN 315 belong to?
FOLLISTATIN 315 is primarily classified as a growth hormone secretion peptide. Peptides that stimulate or support growth hormone release, including GHRH analogs, GHRPs, and direct GH compounds for muscle, recovery, and anti-aging research.
What are the research benefits of FOLLISTATIN 315?
FOLLISTATIN 315 has been studied for: Localized myostatin inhibition, Targeted muscle support, Lean mass preservation. Tissue-bound follistatin isoform; more targeted than FS-344.
Key Studies
40 total on PubMed22 human trialsDynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles
Fujiwara T, Sidis Y, Welt C et al
J Clin Endocrinol Metab
Inhibin subunit mRNA increases with follicle maturity; polycystic ovary syndrome shows reduced inhibin alpha subunit levels
Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice
Canali S, Core AB, Zumbrennen-Bullough KB et al
EndocrinologyAnimal
Activin B stimulates hepcidin via SMAD1/5/8 signaling; follistatin-315 blunts hepcidin induction during inflammation
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential
Datta-Mannan A, Yaden B, Krishnan V et al
J Pharmacol Exp TherPhase 1
Engineered follistatin-Fc fusion showed 100-fold improvement in half-life and robust dose-dependent effects in muscle atrophy models
Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice
Follistatin 315 News
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Follistatin 315 with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Follistatin 315.
Take the Quiz →